Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Weekly Digest
Fed. Cir.

Biogen MA Inc. v. EMD Serono, Inc., No. 19-1133 (Fed. Cir. Sept. 28, 2020)

Errata Correction sheet to a previously issued opinion
Errata
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 19-1133
Decided
September 28, 2020
Judge
—
Document
Errata
Length
1 page
Download Opinion (PDF)

United States Court of Appeals

for the Federal Circuit

November 20, 2020

ERRATA

Appeal No. 2019-1133

BIOGEN MA INC.,

Plaintiff -Appellee

v.

EMD SERONO, INC., PFIZER INC.,

Defendants-Appellants

BAYER HEALTHCARE PHARMACEUTICALS INC., NOVARTIS PHARMACEUTICALS CORPORATION,

Defendants

Decided: September 28, 2020

Precedential Opinion

Please make the following changes:

On page 8, lines 17–20, change “emphasized that whereas the attached carbohydrate groups in native IFN-β protein were glycosolated, the attached carbohydrate groups in recombinant IFN-β were not glycosolated,” to —explained that the glycosylation patterns in native IFN-β and recombinant IFN-β were different,—.

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

Biogen MA Inc. v. EMD Serono, Inc., No. 19-1133 (Fed. Cir. Sept. 28, 2020).

govinfo ID
USCOURTS-ca13-19-01133-2
Permalink
https://patentcasewatch.com/opinions/USCOURTS-ca13-19-01133-2

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.

Source: govinfo.gov USCOURTS collection · retrieved July 25, 2026 · Report an error

Other documents in this case